Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Healthspan Capital is a venture capital firm founded in 2021 and based in El Cerrito, California. The firm specializes in investing in longevity biotechnology ('LongBio') companies that develop therapeutics aimed at extending healthy human lifespan. Established by Sebastian Brunemeier, Nathan Cheng, and Michael Chinen, Healthspan Capital is recognized as the first publicly accessible longevity venture fund listed on AngelList.
Since its inception, Healthspan Capital has become an active player in the longevity biotech sector, completing over 30 deals in under two years. The firm operates with a rolling fund structure, allowing accredited investors to subscribe and invest on a quarterly basis. This model lowers the barrier for limited partners (LPs) and enhances public accessibility to venture capital investments in the longevity space.
Healthspan Capital's investment strategy is focused on early-stage companies, particularly those developing therapies that target aging. The firm is positioned to leverage its expertise and network in the longevity community to support its portfolio companies effectively.
Healthspan Capital invests in early-stage longevity biotech companies, specifically targeting those developing therapeutics that address aging. The firm focuses on investments ranging from pre-Seed to Series A stages, allowing it to engage with startups at critical points in their development. The investment strategy encompasses a variety of methodologies within the longevity biotech sector, including cellular reprogramming, senolytic therapies, metabolic interventions, and regenerative medicine.
The firm’s thesis is that rejuvenation represents the future of medicine, emphasizing the importance of biotechnology startups that aim to slow or reverse aging. Healthspan Capital seeks to partner with founders who are innovative and committed to advancing healthspan and lifespan research. Their geographic focus is primarily on North America, particularly the United States, where they identify promising opportunities in the longevity sector.
Healthspan Capital has built a diverse portfolio of over 25 companies in the longevity biotech space. Notable portfolio companies include:
This portfolio reflects Healthspan Capital's commitment to supporting innovative companies that are at the forefront of longevity research and development.
Nathan Cheng: General Partner. Cheng founded the Longevity Marketcap newsletter and hosts The Longevity Biotech Show podcast. He serves as Program Director at On Deck Longevity Biotech and holds an M.S. in Physics from the University of Toronto. Cheng is a key figure in the longevity community.
Sebastian Brunemeier: General Partner. Brunemeier is the CEO of ImmuneAGE and co-founder of Cambrian Biopharma. He was previously a Principal at Apollo Health Ventures and holds a DPhil from Oxford in aging biochemistry. He has led over 30 longevity deals.
Michael Chinen: General Partner. Chinen is a software engineer and machine learning researcher with experience at Google. He is a former Fulbright Scholar with interests in genome science and aging.
To pitch Healthspan Capital, founders should visit their AngelList rolling fund page. The pitch deck should include a clear overview of the business model, market opportunity, and scientific basis for the proposed therapeutics. Healthspan Capital prefers warm introductions but is open to direct applications through their website.
Response times may vary, but founders can expect to hear back within a few weeks of submission.
Healthspan Capital operates a rolling fund structure through AngelList, allowing accredited investors to subscribe and invest in the fund on a quarterly basis. This model provides flexibility and accessibility for investors interested in the longevity biotech sector.
The firm also includes a Venture Fellows program designed to support deal flow and enhance the investment process.
In 2023, Healthspan Capital has continued to expand its portfolio, completing over 30 deals in the longevity biotech sector. The firm remains active in the investment community, focusing on early-stage companies that align with its mission to extend healthy human lifespan.
Healthspan Capital is also a Tier 5 sponsor of the Aging Research & Drug Discovery Conference (ARDD) 2024, further solidifying its commitment to advancing research in longevity and biotechnology.
What are Healthspan Capital's investment criteria?
Healthspan Capital focuses on early-stage companies in the longevity biotech sector, specifically those developing therapeutics that target aging. They invest in companies at the pre-Seed to Series A stages.
How can I apply or pitch to Healthspan Capital?
Founders can pitch to Healthspan Capital through their AngelList rolling fund page. Interested parties can also reach out via email at info@healthspancapital.vc.
What makes Healthspan Capital different from other venture firms?
Healthspan Capital is the first publicly accessible longevity venture fund listed on AngelList, which allows for broader public participation in investments. Their focus on longevity biotechnology and a rolling fund structure distinguishes them in the venture capital landscape.
What is the geographic scope of Healthspan Capital's investments?
The firm primarily invests in North America, with a strong emphasis on opportunities within the United States.
What is the typical check size for investments?
While specific check sizes are not disclosed, Healthspan Capital invests in early-stage companies, which typically involves smaller initial investments compared to later-stage funding rounds.
What kind of post-investment involvement does Healthspan Capital have?
Healthspan Capital provides value to its portfolio companies through access to a strong network in the longevity community, industry expertise, and support in navigating the complexities of biotechnology development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.